Close

What are ADC's

Our services

ADC Review
is made possible by:




NCT02500914 (Clinical Trial/ SC-002)

Study Title
SC-002 in Small Cell Lung Cancer and Large Cell Neuroendocrine Carcinoma (NCT02500914)

Trial Description
This is a Phase 1a/1b study of SC-002 in patients with relapsed small cell lung cancer (SCLC) and large cell neuroendocrine carcinoma (LCNEC). SC-002 is an antibody-drug conjugate (ADC) comprised of a monoclonal antibody linked to a potent chemotherapy.

The purpose of this study is to assess the safety and tolerability of SC-002 at different dose levels, to determine the highest dose of SC-002 that can be given to patients with SCLC and LCNEC, to evaluate the side effects of SC-002, and to assess the anti-cancer activity of SC-002

This trial is sponsored by Stemcentrx®

Study Data

  • Condition:
    • Small Cell Lung Cancer
    • Large Cell Neuroendocrine Carcinoma
  • Interventions:
    • Drugs used in this trial
      • SC-002
  • Phase: I
  • Estimated Enrollment: 102
  • Start: June 2015
  • Completion: December 2016
  • Last updated: April 2016
  • Last verified: April 2016

Study Schematic

(Coming soon)

Click here to Return to Drug map


Last Editorial review: April 16, 2016
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.

Copyright © 2015 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Add to Flipboard Magazine.


Share

Recommended Articles

Four Ways to Show Nonobviousness of ADC Inventions

05 October, 2018

When the first antibody-drug conjugate (ADC) was approved by the U.S. Food and Drug Administration (FDA) in 2000,[1] only a handful of patent applications claiming ADCs had been published.[2] As research cont...


Skip to toolbar